Annovis Bio (ANVS) Q3 2024 earnings summary

Executive summary

• Focused on late-stage clinical development of Buntanetap for Alzheimer's and Parkinson's diseases, with recent completion of Phase 3 PD and Phase 2/3 AD studies and topline data released in 2024.

• FDA cleared confirmatory Phase 3 studies for buntanetap in early Alzheimer's disease, with studies set to begin in Q1 2025.

• FDA alignment achieved for Phase 3 AD program, with a 6-month and 18-month trial planned; a well-executed 6-month trial may suffice for NDA filing.

• Intellectual property portfolio strengthened with new patents for buntanetap combination therapies.

• No revenue generated; operations funded primarily through equity and warrant issuances.

Financial highlights

• Net loss for Q3 2024 was $12.6 million, an improvement from $14.7 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $18.7 million, down from $34.0 million in the prior year period.

• Operating expenses for Q3 2024 were $4.4 million, down from $14.9 million in Q3 2023, mainly due to reduced R&D spending as clinical trials wound down.

• Cash and cash equivalents as of September 30, 2024 were $12.6 million; as of November 8, 2024, $13.6 million.

• Cash used in operations for the nine months ended September 30, 2024 was $13.6 million, down from $30.6 million in the prior year.

• Raised $4.4 million in net cash from ELOC facility and $7.1 million from Canaccord Warrant exercises during Q3 2024.

Outlook and guidance

• Current cash is expected to fund operations until the initiation of the planned 6-month Phase 3 AD study in Q1 2025; substantial additional capital will be needed for further development and commercialization.

• Preparations underway to begin pivotal Phase 3 AD study in Q1 2025, supported by current liquidity.

• Management plans to raise additional funds through equity, debt, or other alternatives; no assurance of success.